Public Sector Pension Investment Board Has $374.47 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Public Sector Pension Investment Board increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 422,675 shares of the company’s stock after acquiring an additional 61,220 shares during the quarter. Eli Lilly and Company comprises 2.0% of Public Sector Pension Investment Board’s portfolio, making the stock its 5th biggest holding. Public Sector Pension Investment Board’s holdings in Eli Lilly and Company were worth $374,465,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Brown Shipley& Co Ltd grew its stake in Eli Lilly and Company by 10.1% in the 3rd quarter. Brown Shipley& Co Ltd now owns 1,544 shares of the company’s stock valued at $1,368,000 after buying an additional 142 shares during the last quarter. MIG Capital LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $18,234,000. Fiduciary Trust Co grew its position in shares of Eli Lilly and Company by 6.5% in the third quarter. Fiduciary Trust Co now owns 8,561 shares of the company’s stock valued at $7,584,000 after purchasing an additional 522 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Eli Lilly and Company by 1.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 509,199 shares of the company’s stock worth $451,120,000 after purchasing an additional 5,083 shares during the period. Finally, First Commonwealth Financial Corp PA lifted its holdings in Eli Lilly and Company by 0.8% during the 3rd quarter. First Commonwealth Financial Corp PA now owns 2,056 shares of the company’s stock worth $1,821,000 after purchasing an additional 16 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1 %

Shares of NYSE LLY opened at $788.35 on Thursday. The company has a market cap of $748.40 billion, a price-to-earnings ratio of 85.23, a PEG ratio of 2.86 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The stock has a 50-day moving average price of $856.96 and a two-hundred day moving average price of $869.83.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target on the stock. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Citigroup increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.